TECPR2 Research Foundation Partners on Gene Therapy
A new collaboration aims to advance AAV-based treatment for the rare neurodegenerative disease into clinical trials.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Should private partnerships prioritize the development of treatments for ultra-rare genetic diseases?
The TECPR2 Research Foundation has partnered with Forge Biologics to develop an adeno-associated virus (AAV) gene therapy for TECPR2 disorder. This effort seeks to address the genetic root of the neurodegenerative condition, which causes significant developmental and neurological complications.
Why it matters
By combining specialized genetic research with scaled manufacturing, this partnership aims to accelerate the transition of gene therapy from the laboratory to human clinical trials. The program is specifically designed to overcome production barriers common in the development of treatments for ultra-rare diseases.
The program utilizes the FUEL platform, which leverages HEK293 suspension cells—a cell line derived from human embryonic kidney cells used in protein expression—and the pEMBR 2.0 adenovirus helper plasmid to facilitate viral vector production.
The players
TECPR2 Research Foundation
A Boca Raton-based organization focused on funding and coordinating research efforts for the neurodegenerative TECPR2 disorder.
Forge Biologics
A Columbus-based contract development and manufacturing organization that specializes in AAV gene therapy production and process development.
Steven Gray
A researcher at UT Southwestern Medical Center whose lab provides the foundational gene therapy research for the program.
The details
The collaboration centers on developing an AAV vector, a modified harmless virus used as a delivery vehicle to introduce functional genetic material into target cells. Researchers from UT Southwestern Medical Center, led by Steven Gray, provide the foundational science for the therapy. Forge Biologics will handle process development and analytical validation, using its proprietary manufacturing platform to ensure the therapy can be produced at scale.
Timeline
The partnership was formally announced on September 29, 2026.
The Tech Race
This program extends the research trajectory established by the UT Southwestern Medical Center gene therapy pipeline. It reflects a growing industry trend toward outsourcing specialized manufacturing to high-capacity facilities to bridge the gap between academic discovery and clinical-grade production.
This development represents a critical move for patients with TECPR2 disorder, though it remains in the pre-clinical phase. Families and clinicians should look for future announcements regarding regulatory filings and the start of human safety trials.
The takeaway
The program successfully establishes a manufacturing pathway for a rare disease therapy that previously lacked a scalable production model. Stakeholders should monitor the project's progress toward clinical development as an indicator of the viability of current AAV vector scaling platforms.
Further reading
Explore the latest developments in the Biotech sector regarding viral vector manufacturing and clinical trial transitions.
More information
For more information on the research initiatives, visit the TECPR2 Research Foundation website.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should private partnerships prioritize the development of treatments for ultra-rare genetic diseases?
